PBAC's latest decision on Teriparatide: Recommended (2025). Considered for Severe established osteoporosis in postmenopausal women and primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
11
first 2005
Submissions
11
2005 → 2025
Eligible population
Patients with severe established osteoporosis, as per existing PBS criteria for teriparatide (postmenopausal women and men with primary osteoporosis when other agents unsuitable and high fracture risk).
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Key trials
Study TER15
Comparator
Terrosa and Teriparatide Lupin
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
ICER (historical)
$15k/QALY across 4 submissions (2006–2008) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2005: Not recommended · Authority Required
Mar 2006: Not recommended · Authority Required — ICER $45k/QALY
Sep 2006: Not recommended
Nov 2006: ? — ICER $105k/QALY
Nov 2006: Not recommended
Jul 2007: Not recommended · Authority Required — ICER $45k/QALY
Nov 2008: Recommended with restriction · Authority Required — ICER $15k/QALY